GILD  Gilead Sciences Inc.




Health Care


Biotechnology: Biological Products (No Diagnostic Substances)

Market Cap.


Vuru Grade


Current Price

+0.65 (+0.62%)

Growth Price

Overvalued by 74.27%

Stability Price

Overvalued by 85.55%

Company Metrics

  • 18.56 P/E
  • 7.59 P/S
  • 11.6 P/B
  • 5.613 EPS
  • 39.33% Cash ROIC
  • 0.34 Cash Ratio
  • 0 / 0% Dividend
  • 17.20M Avg. Vol.
  • 158.2B Market Cap.

Company Description

Gilead Sciences, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for the treatment of life threatening diseases worldwide. Its products include Atripla, Truvada, Viread, Emtriva for the treatment of human immunodeficiency virus infection in adults; Hepsera, an oral formulation for the treatment of chronic hepatitis B; AmBisome, a amph...

Download 10 Years of Financial Statements:
Income Statement   Balance Sheet   Cash Flow


Gilead Sciences, Inc. Harvoni Gets Preferred Status From UnitedHealth Group ...
Bidness ETC - Jan 29, 2015
Furthermore, Gilead has an advantage because of its exclusivity deal with CVS Health Corp (NYSE:CVS), the second-largest US PBM.
Gilead Sciences, Inc. Is No Longer Just an HIV Company
Motley Fool - Jan 14, 2015
Sure, they've gone from three quarters of Gilead Sciences' revenue to less than half of its revenue, but it's not like sales have decreased.
Can Gilead Sciences, Inc. (GILD) Stock Re-Hit The $100 Mark? - Bidness ETC
Hepatitis C Treatment: Gilead Sciences, Inc. (NASDAQ:GILD) vs. AbbVie Inc ... -
Gilead Sciences, Inc. (GILD) Signs Exclusive Hepatitis C Deal With EnvisionRx
Bidness ETC - Jan 27, 2015
Pharmacy-benefits manager (PBM) EnvisionRx announced Monday that it has signed an exclusive deal with Gilead Sciences, Inc. (NASDAQ:GILD) to list the company's hepatitis C drugs on its formulary. Gilead has clearly taken the lead in the price war ...
Gilead expands hepatitis-C licensing pacts - Business Standard
Gilead expands alliance with Indian partners to include investigational drug - Hindu Business Line
Buzz Stocks: Intercept Pharmaceuticals, Inc., Gilead Sciences, Inc., and The ...
Schaeffers Research (blog) - Jan 30, 2015
Against this backdrop, options traders have been placing bearish bets over bullish at a faster-than-usual clip, per Manitowoc Company Inc's 10-day ISE/CBOE/PHLX put/call volume ratio of 0.80, which ranks in the 60th annual percentile. Echoing this is ...
Will Gilead Sciences, Inc. (GILD) Be Affected As Missouri Sides With AbbVie ...
Bidness ETC - Jan 29, 2015
The Missouri Medicaid program, a 25-state consortium, signed agreements with the company to make Viekira Pak exclusively available, and to remove Gilead Sciences Inc's (NASDAQ:GILD) rival treatment, Solavdi, from preferred formulary status.
3 Ways Gilead Sciences, Inc. Could Still Be in Big Trouble
Motley Fool - Jan 11, 2015
Arguably no biotech stock thrilled investors in 2014 more than Gilead Sciences (NASDAQ: GILD ) . Gilead finished the year up 26%, about double the performance of the broad-market indexes, and the approval and exceptional launch of hepatitis C drugs ...
Prime Gives Preferred Status To Both Gilead Sciences, Inc And AbbVie Hepatitis ... - Bidness ETC
Gilead Sciences Inc.'s (NASDAQ:GILD) Deal with Anthem, Delivers another Blow ... -
Gilead Sciences, Inc (GILD): More Of An HCV-Focused Company Now?
Bidness ETC - Jan 23, 2015
Gilead Sciences, Inc. (NASDAQ:GILD) has steadily shifted its positioning from being a company focused on human immunodeficiency virus (HIV)-related research and development to becoming a hepatitis C virus (HCV)-focused company - all within a span of ...
Express Scripts' Miller says hepatitis C price war to save billions - Reuters UK
3 Big Pharma Stocks With More Free Cash Flow Than Gilead Sciences Inc.
Motley Fool - Jan 18, 2015
Over the past decade Gilead Sciences (NASDAQ: GILD ) has transformed into a veritable pharmaceutical powerhouse, growing its sales from $1.32 billion in 2004 to an estimated $24.3 billion in 2014.
Nomura's Takeaways From Meeting With Gilead Sciences' Management - Benzinga
Gilead Strikes Another Deal - Barron's (blog)
Walt Disney Moves Up In Market Cap Rank, Passing Gilead Sciences
Forbes - Jan 27, 2015
Market capitalization is an important data point for investors to keep an eye on, for various reasons. The most basic reason is that it gives a true comparison of the value attributed by the stock market to a given company's stock. Many beginning ...
Baird Remains Buyers Of Gilead Before Earnings Release
Benzinga - Jan 29, 2015
In a report Thursday morning, analysts at Baird stated that they remain buyers of Gilead Sciences, Inc. (NASDAQ: GILD) before the company's fourth quarter earnings call next Tuesday, February 3. Investors have been concerned that Gilead might ...
Gilead Sciences, Inc. Continues To Reign Over The Hepatitis C Market - Bidness ETC
AbbVie reports better-than-expected 4Q on Humira sales - New Zealand Herald